Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Vladimir Tolmachev

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Anatomy

Tumor Cell Line

Chemicals & Drugs

Concepts & Ideas

Tissue Distribution

Living Beings

Procedures

Disorders

Ovarian Neoplasms

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Tran Thuy A; Rosik Daniel; Abrahmsén Lars; Sandström Mattias; Sjöberg Anna; Wållberg Helena; Ahlgren Sara; Orlova Anna; Tolmachev Vladimir
Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging.
Tolmachev Vladimir; Wållberg Helena; Andersson Karl; Wennborg Anders; Lundqvist Hans; Orlova Anna
The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.
Ekblad Torun; Orlova Anna; Feldwisch Joachim; Wennborg Anders; Karlström Amelie Eriksson; Tolmachev Vladimir
Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Vladimir Tolmachev (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Tran Thuy A; Rosik Daniel; Abrahmsén Lars; Sandström Mattias; Sjöberg Anna; Wållberg Helena; Ahlgren Sara; Orlova Anna; Tolmachev Vladimir
Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging.
European journal of nuclear medicine and molecular imaging 2009;36(11):1864-73.
2009: Tolmachev Vladimir; Wållberg Helena; Andersson Karl; Wennborg Anders; Lundqvist Hans; Orlova Anna
The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.
European journal of nuclear medicine and molecular imaging 2009;36(9):1460-8.
2009: Ekblad Torun; Orlova Anna; Feldwisch Joachim; Wennborg Anders; Karlström Amelie Eriksson; Tolmachev Vladimir
Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules.
Bioorganic & medicinal chemistry letters 2009;19(14):3912-4.
2009: Ahlgren Sara; Wållberg Helena; Tran Thuy A; Widström Charles; Hjertman Magnus; Abrahmsén Lars; Berndorff Dietmar; Dinkelborg Ludger M; Cyr John E; Feldwisch Joachim; Orlova Anna; Tolmachev Vladimir
Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(5):781-9.
2009: Tolmachev Vladimir; Mume Eskender; Sjöberg Stefan; Frejd Fredrik Y; Orlova Anna
Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules.
European journal of nuclear medicine and molecular imaging 2009;36(4):692-701.
2009: Orlova Anna; Wållberg Helena; Stone-Elander Sharon; Tolmachev Vladimir
On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(3):417-25.
2009: Tolmachev Vladimir; Friedman Mikaela; Sandström Mattias; Eriksson Tove L J; Rosik Daniel; Hodik Monika; Ståhl Stefan; Frejd Fredrik Y; Orlova Anna
Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(2):274-83.
2009: Ekblad Torun; Tolmachev Vladimir; Orlova Anna; Lendel Christofer; Abrahmsén Lars; Karlström Amelie Eriksson
Synthesis and chemoselective intramolecular crosslinking of a HER2-binding affibody.
Biopolymers 2009;92(2):116-23.
2008: Tran Thuy A; Ekblad Torun; Orlova Anna; Sandström Mattias; Feldwisch Joachim; Wennborg Anders; Abrahmsén Lars; Tolmachev Vladimir; Eriksson Karlström Amelie
Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules.
Bioconjugate chemistry 2008;19(12):2568-76.
2008: Tolmachev Vladimir; Xu Heng; Wållberg Helena; Ahlgren Sara; Hjertman Magnus; Sjöberg Anna; Sandström Mattias; Abrahmsén Lars; Brechbiel Martin W; Orlova Anna
Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.
Bioconjugate chemistry 2008;19(8):1579-87.
2008: Steffen Ann-Charlott; Göstring Lovisa; Tolmachev Vladimir; Palm Stig; Stenerlöw Bo; Carlsson Jörgen
Differences in radiosensitivity between three HER2 overexpressing cell lines.
European journal of nuclear medicine and molecular imaging 2008;35(6):1179-91.
2008: Nordberg E; Orlova A; Friedman M; Tolmachev V; Ståhl S; Nilsson F Y; Glimelius B; Carlsson J
In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells.
Oncology reports 2008;19(4):853-7.
2008: Friedman Mikaela; Orlova Anna; Johansson Eva; Eriksson Tove L J; Höidén-Guthenberg Ingmarie; Tolmachev Vladimir; Nilsson Fredrik Y; Ståhl Stefan
Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.
Journal of molecular biology 2008;376(5):1388-402.
2008: Ahlgren Sara; Orlova Anna; Rosik Daniel; Sandström Mattias; Sjöberg Anna; Baastrup Barbro; Widmark Olof; Fant Gunilla; Feldwisch Joachim; Tolmachev Vladimir
Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules.
Bioconjugate chemistry 2008;19(1):235-43.
2008: Tolmachev V
Imaging of HER-2 overexpression in tumors for guiding therapy.
Current pharmaceutical design 2008;14(28):2999-3019.
2007: Orlova A; Rosik D; Sandström M; Lundqvist H; Einarsson L; Tolmachev V
Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2007;51(4):314-23.
2007: Tran Thuy; Engfeldt Torun; Orlova Anna; Sandström Mattias; Feldwisch Joachim; Abrahmsén Lars; Wennborg Anders; Tolmachev Vladimir; Karlström Amelie Eriksson
(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
Bioconjugate chemistry 2007;18(6):1956-64.
2007: Engfeldt Torun; Tran Thuy; Orlova Anna; Widström Charles; Feldwisch Joachim; Abrahmsen Lars; Wennborg Anders; Karlström Amelie Eriksson; Tolmachev Vladimir
99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.
European journal of nuclear medicine and molecular imaging 2007;34(11):1843-53.
2007: Persson Mikael; Sivaev Igor; Winberg Karl Johan; Gedda Lars; Malmström Per-Uno; Tolmachev Vladimir
In vitro evaluation of two polyhedral boron anion derivatives as linkers for attachment of radioiodine to the anti-HER2 monoclonal antibody trastuzumab.
Cancer biotherapy & radiopharmaceuticals 2007;22(5):585-96.
2007: Orlova Anna; Feldwisch Joachim; Abrahmsén Lars; Tolmachev Vladimir
Update: affibody molecules for molecular imaging and therapy for cancer.
Cancer biotherapy & radiopharmaceuticals 2007;22(5):573-84.
2007: Orlova Anna; Tran Thuy; Widström Charles; Engfeldt Torun; Eriksson Karlström Amelie; Tolmachev Vladimir
Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.
International journal of molecular medicine 2007;20(3):397-404.
2007: Almqvist Ylva; Steffen Ann-Charlott; Lundqvist Hans; Jensen Holger; Tolmachev Vladimir; Sundin Anders
Biodistribution of 211At-labeled humanized monoclonal antibody A33.
Cancer biotherapy & radiopharmaceuticals 2007;22(4):480-7.
2007: Cheng Junping; Ekberg Tomas; Engström Mats; Nestor Marika; Jensen Holger J; Tolmachev Vladimir; Anniko Matti
Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma.
The Laryngoscope 2007;117(6):1013-8.
2007: Steffen Ann-Charlott; Almqvist Ylva; Chyan Ming-Kuan; Lundqvist Hans; Tolmachev Vladimir; Wilbur D Scott; Carlsson Jörgen
Biodistribution of 211At labeled HER-2 binding affibody molecules in mice.
Oncology reports 2007;17(5):1141-7.
2007: Engfeldt Torun; Orlova Anna; Tran Thuy; Bruskin Alexander; Widström Charles; Karlström Amelie Eriksson; Tolmachev Vladimir
Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.
European journal of nuclear medicine and molecular imaging 2007;34(5):722-33.
2007: Tolmachev Vladimir; Orlova Anna; Nilsson Fredrik Y; Feldwisch Joachim; Wennborg Anders; Abrahmsén Lars
Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy.
Expert opinion on biological therapy 2007;7(4):555-68.
2007: Nilsson Fredrik Y; Tolmachev Vladimir
Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy.
Current opinion in drug discovery & development 2007;10(2):167-75.
2007: Tolmachev Vladimir; Orlova Anna; Pehrson Rikard; Galli Joakim; Baastrup Barbro; Andersson Karl; Sandström Mattias; Rosik Daniel; Carlsson Jörgen; Lundqvist Hans; Wennborg Anders; Nilsson Fredrik Y
Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
Cancer research 2007;67(6):2773-82.
2007: Orlova Anna; Tolmachev Vladimir; Pehrson Rikard; Lindborg Malin; Tran Thuy; Sandström Mattias; Nilsson Fredrik Y; Wennborg Anders; Abrahmsén Lars; Feldwisch Joachim
Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors.
Cancer research 2007;67(5):2178-86.
2007: Tran Thuy; Engfeldt Torun; Orlova Anna; Widström Charles; Bruskin Alexander; Tolmachev Vladimir; Karlström Amelie Eriksson
In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules.
Bioconjugate chemistry 2007;18(2):549-58.
2007: Tran Thuy; Orlova Anna; Sivaev Igor; Sandström Mattias; Tolmachev Vladimir
Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand.
International journal of molecular medicine 2007;19(3):485-93.
2007: Fortin Marc-André; Orlova Anna; Malmström Per-Uno; Tolmachev Vladimir
Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma.
International journal of molecular medicine 2007;19(2):285-91.
2007: Persson Mikael; Gedda Lars; Lundqvist Hans; Tolmachev Vladimir; Nordgren Hans; Malmström Per-Uno; Carlsson Jörgen
[177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.
Cancer research 2007;67(1):326-31.
2007: Nestor Marika; Ekberg Tomas; Dring John; van Dongen Guus A M S; Wester Kenneth; Tolmachev Vladimir; Anniko Matti
Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2007;28(5):253-63.
2006: Almqvist Ylva; Steffen Ann-Charlott; Tolmachev Vladimir; Divgi Chaitanya R; Sundin Anders
In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
Nuclear medicine and biology 2006;33(8):991-8.
2006: Höglund Johanna; Orlova Anna; Sundin Anders; Lundqvist Hans; Tolmachev Vladimir
Cellular processing in the SW1222 cell line of mAb A33 directly and indirectly radiohalogenated.
Oncology reports 2006;16(1):159-63.
2006: Steffen Ann-Charlott; Orlova Anna; Wikman Maria; Nilsson Fredrik Y; Ståhl Stefan; Adams Gregory P; Tolmachev Vladimir; Carlsson Jörgen
Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice.
European journal of nuclear medicine and molecular imaging 2006;33(6):631-8.
2006: Tolmachev Vladimir; Nilsson Fredrik Y; Widström Charles; Andersson Karl; Rosik Daniel; Gedda Lars; Wennborg Anders; Orlova Anna
111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(5):846-53.
2006: Orlova Anna; Magnusson Mikaela; Eriksson Tove L J; Nilsson Martin; Larsson Barbro; Höidén-Guthenberg Ingmarie; Widström Charles; Carlsson Jörgen; Tolmachev Vladimir; Ståhl Stefan; Nilsson Fredrik Y
Tumor imaging using a picomolar affinity HER2 binding affibody molecule.
Cancer research 2006;66(8):4339-48.
2006: Orlova Anna; Bruskin Alexander; Sivaev Igor; Sjöberg Stefan; Lundqvist Hans; Tolmachev Vladimir
Radio-iodination of monoclonal antibody using potassium [125I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (iodo-DABI).
Anticancer research 2006;26(2A):1217-23.
2006: Orlova Anna; Nilsson Fredrik Y; Wikman Maria; Widström Charles; Ståhl Stefan; Carlsson Jörgen; Tolmachev Vladimir
Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(3):512-9.
2006: Persson M I; Gedda L; Jensen H J; Lundqvist H; Malmström P-U; Tolmachev V
Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours.
Oncology reports 2006;15(3):673-80.
2006: Carlsson J; Ren Z P; Wester K; Sundberg A L; Heldin N E; Hesselager G; Persson M; Gedda L; Tolmachev V; Lundqvist H; Blomquist E; Nistér M
Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression.
Journal of neuro-oncology 2006;77(1):33-45.
2005: Persson Mikael; Tolmachev Vladimir; Andersson Karl; Gedda Lars; Sandström Mattias; Carlsson Jörgen
[(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.
European journal of nuclear medicine and molecular imaging 2005;32(12):1457-62.
2005: Mume Eskender; Orlova Anna; Larsson Barbro; Nilsson Ann-Sofie; Nilsson Fredrik Y; Sjöberg Stefan; Tolmachev Vladimir
Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody.
Bioconjugate chemistry 2005;16(6):1547-55.
2005: Velikyan Irina; Sundberg Asa Liljegren; Lindhe Orjan; Höglund A Urban; Eriksson Olof; Werner Eva; Carlsson Jorgen; Bergström Mats; Långström Bengt; Tolmachev Vladimir
Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(11):1881-8.
2005: Kullberg Erika Bohl; Stenerlöw Bo; Ghirmai Senait; Lundqvist Hans; Malmström Per-Uno; Orlova Anna; Tolmachev Vladimir; Gedda Lars
An aminoacridine derivative for radionuclide therapy: DNA binding properties studied in a novel cell-free in vitro assay.
International journal of oncology 2005;27(5):1355-60.
2005: Nestor M; Persson M; van Dongen G A M S; Jensen H J; Lundqvist H; Anniko M; Tolmachev V
In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma.
European journal of nuclear medicine and molecular imaging 2005;32(11):1296-304.
2005: Almqvist Ylva; Orlova Anna; Sjöström Anna; Jensen Holger J; Lundqvist Hans; Sundin Anders; Tolmachev Vladimir
In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma.
Cancer biotherapy & radiopharmaceuticals 2005;20(5):514-23.
2005: Mume Eskender; Orlova Anna; Malmström Per-Uno; Lundqvist Hans; Sjöberg Stefan; Tolmachev Vladimir
Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET.
Nuclear medicine and biology 2005;32(6):613-22.
2005: Steffen Ann-Charlott; Wikman Maria; Tolmachev Vladimir; Adams Gregory P; Nilsson Fredrik Y; Ståhl Stefan; Carlsson Jörgen
In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics.
Cancer biotherapy & radiopharmaceuticals 2005;20(3):239-48.
2005: Babaei Mohammad Hossein; Almqvist Ylva; Orlova Anna; Shafii Mohammad; Kairemo Kalevi; Tolmachev Vladimir
[99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation.
Oncology reports 2005;13(6):1169-75.
2005: Ghirmai Senait; Mume Eskender; Tolmachev Vladimir; Sjöberg Stefan
Synthesis and radioiodination of some daunorubicin and doxorubicin derivatives.
Carbohydrate research 2005;340(1):15-24.
2004: Sandström Mattias; Tolmachev Vladimir; Kairemo Kalevi; Lundqvist Hans; Lubberink Mark
Performance of coincidence imaging with long-lived positron emitters as an alternative to dedicated PET and SPECT.
Physics in medicine and biology 2004;49(24):5419-32.
2004: Orlova Anna; Sjöstrom Anna; Lebeda Ondrej; Lundqvist Hans; Carlsson Jorgen; Tolmachev Vladimir
Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells.
Anticancer research 2004;24(6):4035-41.
2004: Cheng Junping; Persson Mikael; Tolmachev Vladimir; Siavaev Igor; Orlova Anna; Kairemo Kalevi; Anniko Matti
Targeting of a head and neck squamous cell carcinoma xenograft model using the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker.
Acta oto-laryngologica 2004;124(9):1078-85.
2004: Tolmachev Vladimir; Orlova Anna; Wei Qichun; Bruskin Alexander; Carlsson Jörgen; Gedda Lars
Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice.
Cancer biotherapy & radiopharmaceuticals 2004;19(4):491-501.
2004: Wikman M; Steffen A-C; Gunneriusson E; Tolmachev V; Adams G P; Carlsson J; Ståhl S
Selection and characterization of HER2/neu-binding affibody ligands.
Protein engineering, design & selection : PEDS 2004;17(5):455-62.
2004: Winberg Karl Johan; Persson Mikael; Malmström Per-Uno; Sjöberg Stefan; Tolmachev Vladimir
Radiobromination of anti-HER2/neu/ErbB-2 monoclonal antibody using the p-isothiocyanatobenzene derivative of the [76Br]undecahydro-bromo-7,8-dicarba-nido-undecaborate(1-) ion.
Nuclear medicine and biology 2004;31(4):425-33.
2004: Sundberg Asa Liljegren; Gedda Lars; Orlova Anna; Bruskin Alexander; Blomquist Erik; Carlsson Jörgen; Tolmachev Vladimir
[177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma.
Cancer biotherapy & radiopharmaceuticals 2004;19(2):195-204.
2004: Lundqvist Hans; Carlsson Jörgen; Gedda Lars; Tolmachev Vladimir; Garske Ulrike; Kairemo Kalevi
[Radionuclide therapy--a possible way toward an improved treatment of cancer. The obstacle is the shortage of commercially available radionuclides for clinical use]
Läkartidningen 2004;101(11):1000-2, 1005-6.
2004: Bruskin Alexander; Sivaev Igor; Persson Mikael; Lundqvist Hans; Carlsson Jörgen; Sjöberg Stefan; Tolmachev Vladimir
Radiobromination of monoclonal antibody using potassium [76Br] (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closo-dodecaborate (Bromo-DABI).
Nuclear medicine and biology 2004;31(2):205-11.
2004: Tolmachev Vladimir; Carlsson Jörgen; Lundqvist Hans
A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy--availability of suitable radionuclides.
Acta oncologica (Stockholm, Sweden) 2004;43(3):264-75.
2003: Tolmachev V; Orlova A; Lundqvist H
Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides.
Current medicinal chemistry 2003;10(22):2447-60.
2003: Sundberg Asa Liljegren; Almqvist Ylva; Orlova Anna; Blomquist Erik; Jensen Holger J; Gedda Lars; Tolmachev Vladimir; Carlsson Jörgen
Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.
European journal of nuclear medicine and molecular imaging 2003;30(10):1348-56.
2003: Sundberg Asa Liljegren; Orlova Anna; Bruskin Alexander; Gedda Lars; Carlsson Jörgen; Blomquist Erik; Lundqvist Hans; Tolmachev Vladimir
[(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent.
Cancer biotherapy & radiopharmaceuticals 2003;18(4):643-54.
2003: Nestor Marika; Persson Mikael; Cheng Junping; Tolmachev Vladimir; van Dongen Guus; Anniko Matti; Kairemo Kalevi
Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. Comparison with other radioiodination methods.
Bioconjugate chemistry 2003;14(4):805-10.
2003: Sundberg Asa Liljegren; Almqvist Ylva; Tolmachev Vladimir; Carlsson Jörgen
Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition.
European journal of nuclear medicine and molecular imaging 2003;30(5):727-9.
2003: Beshara Soheir; Sörensen Jens; Lubberink Mark; Tolmachev Vladimir; Långström Bengt; Antoni Gunnar; Danielson Bo G; Lundqvist Hans
Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography.
British journal of haematology 2003;120(5):853-9.
2002: Lubberink Mark; Tolmachev Vladimir; Widström Charles; Bruskin Alexander; Lundqvist Hans; Westlin Jan-Erik
110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2002;43(10):1391-7.
2002: Orlova Anna; Höglund Johanna; Lubberink Mark; Lebeda Ondrej; Gedda Lars; Lundqvist Hans; Tolmachev Vladimir; Sundin Anders
Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry.
Cancer biotherapy & radiopharmaceuticals 2002;17(4):385-96.
2002: Lubberink Mark; Lundqvist Hans; Tolmachev Vladimir
Production, PET performance and dosimetric considerations of 134Ce/134La, an Auger electron and positron-emitting generator for radionuclide therapy.
Physics in medicine and biology 2002;47(4):615-29.
2002: Lundqvist Hans; Tolmachev Vladimir
Targeting peptides and positron emission tomography.
Biopolymers 2002;66(6):381-92.
2002: Lindqvist Ulla; Tolmachev Vladimir; Kairemo Kalevi; Aström Gunnar; Jonsson Eva; Lundqvist Hans
Elimination of stabilised hyaluronan from the knee joint in healthy men.
Clinical pharmacokinetics 2002;41(8):603-13.
2000: Mårs U; Tolmachev V; Sundin A
Positron emission tomography of experimental melanoma with.
Nuclear medicine and biology 2000;27(8):845-9.
2000: Höglund J; Tolmachev V; Orlova A; Lundqvist H; Sundin A
Optimized indirect (76)Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate for radioimmuno PET.
Nuclear medicine and biology 2000;27(8):837-43.
2000: Orlova A; Bruskin A; Sjöström A; Lundqvist H; Gedda L; Tolmachev V
Cellular processing of (125)I- and (111)in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells.
Nuclear medicine and biology 2000;27(8):827-35.
2000: Tolmachev V; Bernhardt P; Forssell-Aronsson E; Lundqvist H
114mIn, a candidate for radionuclide therapy: low-energy cyclotron production and labeling of DTPA-D-phe-octreotide.
Nuclear medicine and biology 2000;27(2):183-8.
1999: Lubberink M; Tolmachev V; Beshara S; Lundqvist H
Quantification aspects of patient studies with 52Fe in positron emission tomography.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 1999;51(6):707-15.
1999: Sundin J; Tolmachev V; Koziorowski J; Carlsson J; Lundqvist H; Welt S; Larson S; Sundin A
High yield direct 76Br-bromination of monoclonal antibodies using chloramine-T.
Nuclear medicine and biology 1999;26(8):923-9.
1999: Zhao Q; Tolmachev V; Carlsson J; Lundqvist H; Sundin J; Janson J C; Sundin A
Effects of dextranation on the pharmacokinetics of short peptides. A PET study on mEGF.
Bioconjugate chemistry 1999;10(6):938-46.
1999: Tolmachev V; Koziorowski J; Sivaev I; Lundqvist H; Carlsson J; Orlova A; Gedda L; Olsson P; Sjöberg S; Sundin A
Closo-dodecaborate(2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution.
Bioconjugate chemistry 1999;10(3):338-45.
1999: Garberg P; Engman L; Tolmachev V; Lundqvist H; Gerdes R G; Cotgreave I A
Binding of tellurium to hepatocellular selenoproteins during incubation with inorganic tellurite: consequences for the activity of selenium-dependent glutathione peroxidase.
The international journal of biochemistry & cell biology 1999;31(2):291-301.
1999: Lövqvist A; Lundqvist H; Lubberink M; Tolmachev V; Carlsson J; Sundin A
Kinetics of 76Br-labeled anti-CEA antibodies in pigs; aspects of dosimetry and PET imaging properties.
Medical physics 1999;26(2):249-58.
1999: Beshara S; Lundqvist H; Sundin J; Lubberink M; Tolmachev V; Valind S; Antoni G; Långström B; Danielson B G
Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography.
British journal of haematology 1999;104(2):296-302.
1999: Beshara S; Lundqvist H; Sundin J; Lubberink M; Tolmachev V; Valind S; Antoni G; Långström B; Danielson B G
Kinetic analysis of 52Fe-labelled iron(III) hydroxide-sucrose complex following bolus administration using positron emission tomography.
British journal of haematology 1999;104(2):288-95.
1999: Lubberink M; Lundqvist H; Westlin J E; Tolmachev V; Schneider H; Lövqvist A; Sundin A; Carlsson J
Positron emission tomography and radioimmunotargeting--aspects of quantification and dosimetry.
Acta oncologica (Stockholm, Sweden) 1999;38(3):343-9.
1999: Lundqvist H; Lubberink M; Tolmachev V; Lövqvist A; Sundin A; Beshara S; Bruskin A; Carlsson J; Westlin J E
Positron emission tomography and radioimmunotargeting--general aspects.
Acta oncologica (Stockholm, Sweden) 1999;38(3):335-41.
1999: Carlsson J; Blomquist E; Gedda L; Liljegren A; Malmström P U; Sjöström A; Sundin A; Westlin J E; Zhao Q; Tolmachev V; Lundqvist H
Conjugate chemistry and cellular processing of EGF-dextran.
Acta oncologica (Stockholm, Sweden) 1999;38(3):313-21.
1998: Bergström M; Lu L; Fasth K J; Wu F; Bergström-Pettermann E; Tolmachev V; Hedberg E; Cheng A; Långström B
In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(7):1273-9.
1998: Zhao Q; Blomquist E; Bolander H; Gedda L; Hartvig P; Janson J; Lundqvist H; Mellstedt H; Nilsson S; Nistèr M; Sundin A; Tolmachev V; Westlin J; Carlsson J
Conjugate chemistry, iodination and cellular binding of mEGF-dextran-tyrosine: preclinical tests in preparation for clinical trials.
International journal of molecular medicine 1998;1(4):693-702.
1998: Tolmachev V; Lundqvist H; Einarsson L
Production of 61Cu from a natural nickel target.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 1998;49(1-2):79-81.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Vladimir Tolmachev

Research Profile (preview)

Anatomy

Chemicals & Drugs

Concepts & Ideas

Living Beings

Procedures

Disorders

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Vladimir Tolmachev (preview)

All Publications